Status:
RECRUITING
Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
Lead Sponsor:
Scarborough General Hospital
Collaborating Sponsors:
Scarborough Health Network
Lakeridge Health Corporation
Conditions:
Critical Illness
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium ...
Detailed Description
Background: Measurement of serum magnesium levels, and administration of supplemental magnesium when levels are below target, is a common element of routine care for critically ill patients. However, ...
Eligibility Criteria
Inclusion
- Age 16 years or older
- Admission orders written to a medical-surgical intensive care unit at a participating site
- Magnesium replacement protocol ordered
Exclusion
- Prior enrollment in or withdrawal from MAGNOLIA trial
- Sustained ventricular tachycardia
- Pre-eclampsia
- Myasthenia gravis
Key Trial Info
Start Date :
November 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
3253 Patients enrolled
Trial Details
Trial ID
NCT07173855
Start Date
November 25 2025
End Date
June 1 2027
Last Update
December 31 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Lakeridge Health Ajax-Pickering
Ajax, Ontario, Canada, L1S 2J4
2
Lakeridge Health Oshawa
Oshawa, Ontario, Canada, L1G 8A2
3
Scarborough Centenary Hospital
Toronto, Ontario, Canada, M1E 4B9
4
Scarborough General Hospital
Toronto, Ontario, Canada, M1P2V5